| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 424161100 | Hepatitis virus | 16 |
| 20080279863 | THERAPEUTIC ANTIBODIES FOR TREATMENT AND PROPHYLAXIS OF TRANSMITTABLE VIRAL DISEASES - The invention provides methods and compositions for the treatment and prevention of a transmittable disease in a subject, such as avians and mammals. The methods and compositions of the invention specifically make use of avian antibodies to the disease to be treated or prevented. Administration of such avian antibodies to a subject has been shown effective for reducing mortality in a population of subjects that are infected, or become infected, with the disease. The invention also provides kits useful for detecting the presence of transmittable diseases in subjects. | 11-13-2008 |
| 20090104207 | Hepatitis C Virus Neutralizing Antibodies - The invention relates to anti-HCV antibodies and more specifically to neutralizing anti-HCV antibodies and their variable and complementarity determining regions (CDR). In particular, the neutralizing anti-HCV antibodies are neutralizing anti-HCV envelope protein 1 (HCV E1) antibodies. Also subject of the invention are compositions comprising these antibodies, CDRs or variable regions, and compounds comprising at least one of the CDRs or variable regions of said antibodies. Further subject of the invention are the application of any of said antibodies, CDRs, variable regions or compounds in HCV prophylaxis, therapy, and diagnosis, as well as methods for producing the antibodies. | 04-23-2009 |
| 20090110685 | Treatment and prevention of viral infections - Disclosed is polynucleotide encoding a polypeptide comprising an antibody binding site, the polypeptide being able to bind to HCV E2 samples representative of each of HCV genotypes 1-6, as well as polypeptides having such properties and uses of such polypeptides in detecting and treating HCV infection. | 04-30-2009 |
| 20100143378 | Subcutaneous Administration of Anti-Hepatitis B Antibodies - The present application relates to an immunoglobulin preparation comprising anti-hepatitis B antibodies for subcutaneous administration and to uses thereof, including methods for treating, preventing and/or reducing a disease, disorder or condition associated with hepatitis B virus. | 06-10-2010 |
| 20100255001 | BLOCKERS OF SEROTONIN AND ITS RECEPTORS FOR THE TREATMENT OF HEPATITIS - The present invention relates to a method of treating hepatitis comprising administering a serotonin blocker, and the use of such blockers in said treatment and in the manufacture of medicaments for treating hepatitis. | 10-07-2010 |
| 20100330099 | STABILIZED ANTI-HEPATITIS B (HBV) ANTIBODY FORMULATIONS - The present invention provides liquid formulations of antibodies or fragments thereof that specifically bind to a hepatitis B virus (HBV) antigen, which formulations exhibit stability, low to undetectable levels of aggregations, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. Furthermore, the invention provides methods of preventing, treating or ameliorating one or more symptoms associated with HBV infection utilizing the liquid formulations of the present invention. | 12-30-2010 |
| 20110014209 | RECOMBINANT HCV E2 GLYCOPROTEIN - The invention provides modified hepatitis C virus (HCV) E2 glycoproteins comprising the HCV-E2 receptor-binding domain (RBD) including the HVR1, HVR2 and igVR variable regions wherein in at least one of said variable regions at least a part of the variable region is replaced with a flexible linker sequence. The invention also provides vaccine compositions comprising the modified glycoproteins as well as methods of use thereof. | 01-20-2011 |
| 20110311550 | AGENTS FOR HCV TREATMENT - Provided are polypeptides, including antibodies and fragments thereof, useful for preventing or treating new or recurring infection of hepatitis C virus, as well as methods of preventing or treating new or recurring hepatitis C viral infection. Also provided are modified E1 and E2 polypeptides. | 12-22-2011 |
| 20110311551 | ANTIBODIES DIRECTED AGAINST HEPATITIS C VIRUS E1E2 COMPLEX, COMPOSITIONS OF HCV PARTICLES, AND PHARMACEUTICAL COMPOSITIONS - The invention provides new conformational antibodies, and more particular conformational monoclonal antibodies and fragments thereof, that are directed against HCV. Also provided are compositions of particles that are recognized by such antibodies, and pharmaceutical compositions containing these particles. Also described are HCV enveloped subviral particles and purified HCV enveloped complete viral particles, as well as processes for their preparation. | 12-22-2011 |
| 20120034238 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS VIRUS INFECTION - The present invention relates to a method for treating hepatitis virus infection comprising administering to a subject infected with a hepatitis virus an effective amount of a yolk or yolk antibody obtained from an egg of a fowl which has been immunized using | 02-09-2012 |
| 20120308580 | HEPATITUS B VIRUS SPECIFIC ANTIBODY AND USESE THEREOF - There is provided at least one isolated TCR-like antibody or fragment thereof, wherein the antibody or fragment thereof is capable of specifically binding to at least one HBV derived peptide. | 12-06-2012 |
| 20130084301 | Cluster of Neutralizing Antibodies to Hepatitis C Virus - Compositions and methods are provided relating to human anti-HCV E2 monoclonal antibodies. The antibodies of the invention bind to a conserved region of HCV E2 protein, and neutralize HCV influenza virus across multiple HCV genotypes. Embodiments of the invention include isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the human anti-HCV monoclonal antibodies; and cell lines that produce these monoclonal antibodies. | 04-04-2013 |
| 20140271669 | METHODS TO PRODUCE A HUMAN PLASMA-DERIVED IGG PREPARATION ENRICHED IN BRAIN DISEASE-RELATED NATURAL IGGS - The present invention provides, among other aspects, methods for the manufacture of plasma-derived immunoglobulin G compositions highly enriched for anti-brain disease related protein antibodies (e.g., anti-Aβ, anti-RAGE, and anti-α-synuclein antibodies). Advantageously, the methods provided do not affect the manufacturing processes or capabilities for producing plasma-derived IgG therapeutics. Plasma-derived IgG compositions that are highly enriched for anti-brain disease related protein antibodies (e.g., anti-Aβ, anti-RAGE, and anti-α-synuclein antibodies), as also provided here. Methods for the treatment of brain diseases and disorders by administration of plasma-derived IgG compositions highly enriched for anti-brain disease related protein antibodies (e.g., anti-Aβ, anti-RAGE, and anti-α-synuclein antibodies), are also provided. | 09-18-2014 |
| 20140294858 | SUBCUTANEOUS ADMINISTRATION OF ANTI-HEPATITIS B ANTIBODIES - The present application relates to an immunoglobulin preparation comprising anti-hepatitis B antibodies for subcutaneous administration and to uses thereof, including methods for treating, preventing and/or reducing a disease, disorder or condition associated with hepatitis B virus | 10-02-2014 |
| 20160024186 | Biological Therapeutics for Infection-Relating Disorders or Conditions - The present invention discloses products and the methods of uses of the products for preventing and treating infectious diseases and the disorders or conditions inducible by harmful antibodies. The harmful antibodies are induced during infection, or vaccination, or use of therapeutic antibodies. The products of the present disclosure comprise immunoglobulin products, serum or plasma, specific antibodies to viral pathogens. | 01-28-2016 |
| 20170233458 | METHOD OF MANUFACTURING INTRAVENOUS IMMUNOGLOBULIN FROM FRACTION III | 08-17-2017 |
